Co-Diagnostics reports FY2022 revenue of $34.2M, down 65% YoY; net loss $0.45/share

Co-Diagnostics, Inc.

Revenue $34.2M, down from $97.9M in 2021 due to lower COVID-19 test demand.
Net loss $14.2M ($0.45 diluted EPS) vs net income $36.7M ($1.23) prior year.
Operating loss $27.0M, driven by lower revenue, goodwill impairment, R&D for Co-Dx PCR Home.
Adjusted net income (excl. goodwill) $1.2M, or $0.04 per diluted share.
Initiated clinical evaluations for Co-Dx PCR Home platform; cash $81.3M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Co-Diagnostics, Inc. reported the full year ended December 31, 2022 results: revenue $34.2 million, net income $14.2 million, EPS $0.45 per fully diluted share.

Period: the full year ended December 31, 2022
Revenue: $34.2 million
Net income: $14.2 million
EPS: $0.45 per fully diluted share
Result: reported results

Exact text from the filing

the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022. Full Year 2022 Financial Results: ● Revenue of $34.2 million, down from $97.9 million during the prior year primarily due to lower global demand for the Logix SmartTM COVID-19 tests ● Gross profit of $28.7 million, representing 84.0% of

View on SEC.gov

Browse all earnings releases →

Co-Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-007900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.